Q-omics provides the consensus-scored RNVU1-22 profile across patient tissues and cancer cell-line models. RNVU1-22 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RNVU1-22 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, RNVU1-22 RNA expression shows 10,640 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, THCA, and LSCC as cancer lineages where RNVU1-22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNVU1-22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNVU1-22 survival associations across molecular data types. RNVU1-22 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNVU1-22 RNA expression–survival associations across cancer types. High RNVU1-22 expression shows unfavorable associations in LIHC, CESC, ESCA, KIRC and SKCM, but favorable associations in PAAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RNVU1-22 RNA expression.
This table summarizes RNVU1-22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNVU1-22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNVU1-22 shows lower tumor expression in THCA and HNSC and higher tumor expression in STAD, KICH, LUSC and LIHC. The THCA box plot shows higher RNVU1-22 RNA expression in normal versus tumor tissue (log2 FC = −0.728, t-test p < 0.001).
This table shows molecular features associated with RNVU1-22 in patient tissues and cancer cell lines. In patient samples, RNVU1-22 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
